Abstract
BackgroundIn CheckMate 9LA, nivolumab plus ipilimumab with chemotherapy prolonged overall survival (OS) versus chemotherapy regardless of tumor PD-L1 expression or histology. We report updated efficacy and safety in all randomized...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have